Rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is a immune modulator blocking its interactions could strengthen immune cells' attack on cancer.
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.
Request a free trialInvestor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.
Request a free trial